Insulin initiates diverse hepatic metabolic responses, including gluconeogenic suppression and induction of glycogen synthesis and lipogenesis 1, 2 . The liver possesses a rich sinusoidal capillary network with a higher degree of hypoxia and lower gluconeogenesis in the perivenous zone as compared to the rest of the organ 3 . Here, we show that diverse vascular endothelial growth factor (VEGF) inhibitors improved glucose tolerance in nondiabetic C57BL/6 and diabetic db/db mice, potentiating hepatic insulin signaling with lower gluconeogenic gene expression, higher glycogen storage and suppressed hepatic glucose production. VEGF inhibition induced hepatic hypoxia through sinusoidal vascular regression and sensitized liver insulin signaling through hypoxia-inducible factor-2a (Hif-2a, encoded by Epas1) stabilization. Notably, liverspecific constitutive activation of HIF-2a, but not HIF-1a, was sufficient to augment hepatic insulin signaling through direct and indirect induction of insulin receptor substrate-2 (Irs2), an essential insulin receptor adaptor protein [4] [5] [6] . Further, liver Irs2 was both necessary and sufficient to mediate Hif-2a and Vegf inhibition effects on glucose tolerance and hepatic insulin signaling. These results demonstrate an unsuspected intersection between Hif-2a−mediated hypoxic signaling and hepatic insulin action through Irs2 induction, which can be co-opted by Vegf inhibitors to modulate glucose metabolism. These studies also indicate distinct roles in hepatic metabolism for Hif-1a, which promotes glycolysis [7] [8] [9] , and Hif-2a, which suppresses gluconeogenesis, and suggest new treatment approaches for type 2 diabetes mellitus.
The liver regulates systemic energy reserves by controlling carbo hydrate and lipid metabolism in response to dietary and systemic cues. Hepatic insulin stimulation recruits insulin receptor substrate (IRS) proteins to the insulin receptor, activating protein kinase B (AKT), glycogen synthase kinase3β (GSK3β) and mammalian target of rapamycin; these signals coordinately suppress hepatic gluconeo genesis and induce glycogen synthesis and lipogenesis 1, 2 . The liver perivenous zone experiences relative hypoxia accompanied by sup pression of gluconeogenesis 3 . During normoxia, prolyl hydroxylase domain-containing enzymes (PHD1, PHD2 and PHD3) and FIH (factor inhibiting hypoxiainducible factor (HIF)) hydroxylate mem bers of the HIF transcription factor family (HIF1, HIF2 and HIF3), resulting in von HippelLindau tumor suppressor (VHL)dependent proteosomal degradation; hypoxic inhibition of this hydroxylation stabilizes HIFs and induces HIF transcriptional targets 10 .
The VEGF family contains VEGFA, VEGFB, VEGFC, VEGFD and placental growth factor (PlGF), each with distinct affinities for VEGF receptors 1-3 (VEGFR1, VEGFR2 and VEGFR3) and neuro pilins. VEGFR1 (FLT1) is a highaffinity receptor for VEGFA, VEGFB and PlGF, whereas VEGFR2 (Flk1/KDR) is a lowaffinity receptor for VEGFA, VEGFC and VEGFD 11, 12 . VEGF inhibitors have been reported to decrease fasting blood glucose levels and improve glucose tolerance in mice and humans through unclear mechanisms 13, 14 , and specific Vegfb inhibition improves glucose tolerance through enhanced peripheral glucose uptake 15 . Here, we used single intra venous (i.v.) injections of adenoviruses encoding the soluble extracel lular ligandbinding domains of mouse Vegfr1 (AdsFlt1) or of Vegfr2 fused to an antibody Fc (AdsFlk1) to achieve hepatic secretion of Flt1 or Flk1 ectodomains into the circulation; both ectodomains elicit potent and durable Vegfa neutralization in vivo 16, 17 . An adenovirus encoding a mouse immunoglobulin IgG2α Fc fragment (AdFc) was used as a negative control 16, 17 . In C57BL/6 mice, AdsFlt1-mediated Vegf inhibition improved the response to intraperitoneal (i.p.) glu cose injection compared to AdFc injection in both glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) (Fig. 1a) . Moreover, in l e t t e r s diabetic db/db mice, the results of GTT and ITT tests were again mark edly improved by either AdsFlt1 or AdsFlk1 compared to control AdFc treatment (Fig. 1b) ; all results were confirmed by areaunder thecurve (AUC) analysis (Supplementary Fig. 1a-d) . Recombinant aflibercept (VEGF Trap) encodes a fusion of human VEGFR1 and VEGFR2 ectodomains with human IgG1 Fc that potently sequesters and neutralizes VEGFA, VEGFB and PlGF 18, 19 . Severe combined immunodeficient (SCID) and db/db mice treated with aflibercept also showed greater improvement in glucose tolerance compared to con trols treated with a control human Fc immunoglobulin fragment (hFc) (Fig. 1c,d and Supplementary Fig. 1e,f) ; SCID mice were used to eliminate potential neutralizing antibody responses against aflibercept. Similar results were obtained with both the anti-VEGFA monoclonal antibody (mAb) B20. 4 Fig. 1g,h) , neither of which interferes with VEGFB signaling.
AdsFlt1, aflibercept or DC101 decreased fasting or fed glucose levels in C57BL/6 (AdsFlt1 and DC101), SCID (aflibercept) or db/db (aflibercept) mice (Supplementary Fig. 2a-e) , and aflibercept did not increase plasma insulin or decrease glucagon ( Supplementary  Fig. 2f,g ). In a hyperinsulinemiceuglycemic clamp study, C57BL/6 mice treated with aflibercept for 2 weeks exhibited greater insulin sensitivity and enhanced insulininduced suppression of hepatic glucose production (HGP) (Fig. 1e and Supplementary Fig. 3 ). Further, in db/db mice, aflibercept substantially lowered hyper insulinemia compared to control hFc treatment (Fig. 1f) . This occurred without altering insulinstimulated wholebody glucose disposal, tissuespecific glucose uptake in the periphery or hepatic cAMP response element-binding protein or AMPactivated protein kinase (AMPK) signaling (Supplementary Fig. 4a,b) .
The insulinpotentiating effects of VEGF inhibition on HGP prompted us to evaluate insulin receptor signaling in mouse liver. AdsFlt1 treatment increased phosphorylation of Akt (pAkt) and Gsk3β (p-Gsk3β), as did aflibercept for pAkt (Fig. 1g,h ). Both AdsFlt1 and aflibercept augmented expression of Irs2 and suppressed phosphoenolpyruvate carboxykinase (Pck1) and glucose6phosphatase npg catalytic subunit (G6pc) expression compared to AdFc or hFc con trols ( Fig. 1g-j) ; however, alterations of Irs1 or insulin receptor βchain expression were not observed in aflibercept and AdsFlttreated mice, respectively ( Fig. 1g,h ). We observed similar effects with AdsFlk1 treatment ( Fig. 1i and Supplementary Fig. 4c,d ). Both sFlt1 and sFlk1 repressed liver G6pc and elevated glycogen in fasted liver compared to AdFc-treated mice ( Supplementary Fig. 4e ), again consistent with hepatic insulin signaling sensitization. Vegf inhibition induces capillary regression in both normal adult organs and solid tumors, although effects in liver have not been described 13, 22, 23 . AdsFlt1, AdsFlk1 and recombinant aflibercept induced marked and reversible regression of CD31 + hepatic sinu soids compared to AdFc-and hFctreated controls (Fig. 2a,b and Supplementary Fig. 5a,b) , as did DC101 and B20.4.1.1 ( Supplementary Fig. 5c,d) . A FACSbased hypoxyprobe method detected a hypoxic shift in liver upon in vivo VEGF antago nism ( Fig. 2c ) that was not seen in Fctreated animals. AdsFlt1 and aflibercept also decreased functional perfusion in mouse liver upon intravascular biotin infusion (Fig. 2d) . Further, microarray analysis of aflibercepttreated mouse liver revealed upregulation of several hypoxiainducible genes, including Cited2, Loxl2 and Pfkl ( Supplementary Fig. 6a ), whereas Hif2α but not Hif1α protein was stabilized in AdsFlt1-treated mouse liver (Fig. 2e) . Notably, AdsFlt1 improved glucose tolerance in unexcised Epas1 flox/flox mice (here called Hif2α flox mice), but this effect was significantly blunted in mice with liverspecific Epas1 deletion (Epas1 flox/flox ; albuminCre mice, here called Hif2α LKO mice) 9 ( Fig. 2f and Supplementary  Fig. 7a) . Similarly, AdsFlt1-mediated induction of hepatic Irs2 expression, Akt or Gsk3β phosphorylation and AdsFlt1 suppres sion of G6pc were all blunted in Hif2α LKO in comparison to Hif2α flox mice (Fig. 2g,h ), indicating that Vegf inhibition utilizes hepatic Hif2α to sensitize liver insulin signaling. Additionally, adenoviral shRNA knockdown of liver Hif2α also reversed the effects of sFlt1 on glucose tolerance and insulin signaling (Supplementary Fig. 7b-e) .
We next examined whether hepatic Hif2α activation was suf ficient to augment liver insulin receptor signaling. Hepatic adeno viral expression of a constitutively active HIF2α variant mutated at inhibitory hydroxylation sites Pro531 and Asn847 (AdHIF2αPN) or lacking the inhibitory oxygendependent degradation domain (ODD) (AdHIF2α∆ODD) significantly decreased blood glucose under fed or fasted conditions and improved both glucose tolerance and insulin sensitivity compared to mice treated with either AdFc or adenovirus encoding a HIF1α∆ODD mutant (AdHIF1α∆ODD). (Fig. 3a and Supplementary Fig. 8a-f) . Similarly, AdHIF2αPN or AdHIF 2α∆ODD was much more effective than AdHIF1α∆ODD or AdFc at inducing hepatic Irs2 protein and amounts of pAkt, p-Gsk3β and (Fig. 3b,c and Supplementary  Fig. 8g ). In parallel, HIF2α constitutive activation repressed G6pc and Pck1 expression more strongly than did HIF1α ( Fig. 3d and Supplementary Fig. 8h ). In primary mouse hepatocytes, HIF2α but not HIF1α activation markedly induced Irs2 expression and syn ergized with insulin to increase Akt phosphorylation compared to controls, indicating a cellautonomous mechanism (Fig. 3e) .
We explored the functional relevance of Irs2 to Hif2α regulation of hepatic insulin signaling both in vitro and in vivo. In primary hepato cytes, the synergistic activation of Akt phosphorylation by AdHIF 2αPN and insulin was attenuated by Irs2 knockdown (AdshRNA Irs2) (Fig. 3f) . Further, in db/db mice, the ability of AdHIF2αPN to improve glucose tolerance, increase liver Akt phosphorylation and repress G6pc was attenuated by concomitant Irs2 knockdown (Fig. 3g,h and Supplementary Fig. 8i ). Hepatic IRS2 overexpression through AdIRS2 (ref. 24 ) markedly improved glucose tolerance in db/db mice compared to AdFc-treated controls in agreement with previous results 24 . The ability of liver IRS2, AdHIF2αPN and VEGF inhibi tion to phenocopy each other in GTT (Fig. 3i and Supplementary  Fig. 8j ) is consistent with liver Irs2 induction being itself sufficient to mediate the effects of AdHIF2αPN or Vegf inhibition on glucose tolerance. Similarly, AdsFlt1 improvement of glucose tolerance was also attenuated by liver Irs2 shRNA knockdown (Fig. 3j) .
HIF2α induced liver Irs2 mRNA expression both in vivo and in primary hepatocytes (Fig. 4a,b) , which suggested that Hif2α could directly regulate Irs2 transcription. Canonical hypoxia response ele ments (HREs) are present at nucleotide positions -900 and -123 in the mouse and human IRS2 promoter regions (Fig. 4c) . The proximal -123 but not the distal -900 HRE was required for HIF2α transacti vation of an IRS2luciferase reporter construct in insulinstarved H2 hepatoma cells; notably, HIF1α was ineffective (Fig. 4c) , and both HIF1α and HIF2α potently activated 5× HRE luciferase constructs (data not shown). Additionally, microarray analysis of aflibercept treated mouse liver revealed downregulation of numerous Srebp1c (Srebf) target genes (Supplementary Fig. 6b ). In addition to its well described lipogenic functions and induction by feeding or insulin 1 , SREBP1c represses Irs2 in fed or fasted mice by competitively inhib iting FOXO transcription factor binding to Irs2 promoter insulin responsive elements 25 . Further, liver Srebf1 and Irs2 expression are inversely correlated in multiple settings 25, 26 , suggesting possible Hif2α induction of Irs2 through Srebf1 repression. Constitutive HIF2α activation through AdHIF2αPN potently abrogated both insulinstimulated Srebf1 expression in primary hepatocytes (Fig. 4d) and Srebf1 expression in fed mice (Fig. 4e) . However, HIF1α activation also lowered Srebf1 mRNA levels (Fig. 4e) without affecting glucose tolerance or inducing IRS2 (Fig. 3 and Supplementary Fig. 8a-g ), 
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suggesting that Srebf1 repression was not itself sufficient for HIF2α induction of Irs2. Forced adenoviral overexpression of a cleaved active form of SREBP1c (AdnSREBP1c) 27 reversed AdHif2αPN stimula tion of Irs2 both in insulinstarved primary hepatocytes (Fig. 4f) and in vivo under refed conditions (Fig. 4g) . Thus, HIF2α suppression of the Irs2 repressor Srebf1, although not itself sufficient, appears to facilitate HIF2α−Irs2 direct transactivation (Fig. 4h) . These studies reveal a previously unsuspected crosstalk between the liver hypoxia and insulin signaling pathways whereby Hif2α strongly augments insulindependent Akt activation and gluconeogenic sup pression (Fig. 4h) . Here, complementary in vitro and in vivo studies demonstrate that Hif2α positively regulates hepatic insulin signal ing by upregulating Irs2. This Irs2 induction is specific to HIF2α and not HIF1α activation, paralleling studies where the former and not the latter has a dominant role in regulation of hepatic Epo 9,28 , Pou5f1, Ccnd1 and Dmrt1 (refs. 29-31) and of liver lipogenesis 32 . In knockdown and overexpression studies, liver Irs2 is both necessary and sufficient for Hif2α-mediated improvement of glucose tolerance and hepatic insulin signaling. The improved glucose tolerance upon liver IRS2 overexpression is in agreement with prior studies where increased hepatic IRS2 expression is fully sufficient to ameliorate diabetes in db/db mice and activate fasted liver insulin signaling 24 .
Although we have established a clear functional role for Irs2, we cannot fully exclude parallel Irs2independent pathways. Possibilities for Irs2independent Hif2α effects include insulinindependent direct association of peroxisome proliferator-activated receptor γ coactivator1α, hepatocyte nuclear factor4 or CCAAT enhancerbinding protein with Pck1 and G6pc promoter elements 32, 33 . Alternatively, erythropoietin has been variously reported to either improve peripheral glucose uptake 34 or inhibit gluconeogenesis by modulation of inflammation 35 , although erythropoietin does not induce liver IRS2 (S.M.P. and C.J.K., unpublished data). Our demon stration that the Hif2α-Irs2 axis couples hypoxia sensing to gluco neogenic repression through potentiation of hepatic insulin signaling complements observations of hypoxic regulation of IRS2 and invasion in breast cancer cells 36 . Notably, upon hepatic Vhl deletion, which stabilizes both Hif2α and Hif1α, a Srebf1 gene signature is induced by superimposed deletion of Epas1 but not Hif1a, suggesting the pos sibility of Hif2α-specific Srebf1 repression 32 . Hif2α induced Irs2 but decreased Irs1 expression, suggestive of potential reciprocal regula tion; however, liver Irs1 downregulation typically impairs rather than improves glucose tolerance 4, 5 .
The beneficial effects of Hif2α on animal models of insulin resist ance suggest the potential therapeutic utility of prolyl hydroxylase inhibitors that block VHLdependent HIF degradation for type 2 diabetes mellitus therapy. This could occur through isoform specific PHD3 pharmacologic inhibition (see accompanying paper by Taniguchi et al. 37 ) that could circumvent the hepatic lipid accumulation associated with conventional liver HIF2α activa tion 32, 38 . A second strategy for pharmacologic manipulation of the hepatic Hif2α-Irs2 axis is represented by Vegf inhibition, which decreases pancreatic islet microvessel density 13 with specific Vegfb npg antagonism in mice enhancing peripheral glucose uptake 15 . However, aflibercept, a clinically used therapeutic that binds VEGFA, VEGFB and PlGF 18 , here acts on liver through insulin sensitization rather than on skeletal muscle. Such alternative mechanisms are fur ther supported by the abilities of sFlt1 and of non-Vegfb-targeting inhibitors such as sFlk1, B20.4.1.1 and DC101 to modulate glucose tolerance, hepatic insulin signaling or both. Conceivably, inhibition of Vegfa or Vegfb could coordinately regulate glucose metabolism through hepatic insulin signaling and peripheral glucose uptake, respectively 15 , with additional mechanisms certainly possible. Because HIF2α and HIF1α exhibit similar hypoxic stabilization profiles 39 , the specific Vegfinhibitor stabilization of Hif2α over Hif1α could occur through selective Phd3 inhibition (see accompanying manu script by Taniguchi et al. 37 ) or alternative nonhypoxic pathways 17 and could underlie observations of improved glucose control in VEGF inhibitor-treated patients with diabetes 14 . As constitutive HIF2α activation induces insulin receptor signaling endpoints more strongly than Vegf inhibitors, additional asyetundetermined pathways may contribute to effects of Vegf blockade and hypoxic signaling on hepatic glucose metabolism. Finally, any therapeutic use of either pro lyl hydroxylase inhibitors or VEGF inhibitors for diabetes would need to be carefully balanced against known doselimiting and chronic toxicities of these agents. Overall, our data indicate distinct roles in energy metabolism for hepatic Hif2α, which sensitizes liver insulin signaling and suppresses gluconeogenesis, and hepatic Hif1α, which promotes glycolysis [7] [8] [9] . In vivo, physiologic perivenous liver hypoxia 3 could trigger the Hif2α-Irs2 axis, preferentially enhance insulin signaling and suppress perivenous Pck1 and G6pc, explaining the previously observed enrichment of gluconeogenesis in the periportal zone 3 . Finally, the mechanistic interplay in liver between the hypoxia/Hif2α and insulin receptor signaling pathways, as demonstrated here, has potentially broad implications for the study of metabolism and thera peutic approaches to type 2 diabetes mellitus.
METHods
Methods and any associated references are available in the online version of the paper. Accession codes. Microarray data were deposited in the NCBI Gene Expression Omnibus (GEO) with accession code GSE50519. extraction and gene expression analysis. For in vitro insulin stimulation assay, freshly harvested mouse primary hepatocytes were cultured in serum over night. Adenoviruses were added to serumfree medium 12 h after plating for 24 h at a multiplicity of infection (m.o.i.) of 10 (AdFc, AdHIF2αPN and AdHIF1α ∆ODD) or MOI of 20 (AdshRNA Irs2 and AdshRNA luci ferase). Following adenoviral infection, cells were stimulated with 100 nM bovine pancreas insulin (Sigma) for 10 min followed by protein extraction and western blotting. For in vitro Irs2 and Srebf1 expression analysis, primary hepatocytes were infected with adenovirus 12 h after plating for 24 h at an m.o.i. of 10 in serumfree medium. After 24 h, cells were stimulated with 10 nM insulin for 6 h. RNA was extracted and qRTPCR was performed as described above.
Lectin perfusion. Adult C57BL/6 mice received single i.v. injection of AdFc, AdsFlt1 or AdVEGF Trap (aflibercept) 17 (encoding the aflibercept coding sequence) at 1 × 10 9 PFU each. At day 22, mice were anesthetized with Avertin. 100 µl of biotinylated L. esculentum lectin (1 mg/ml in 0.9% NaCl; Vector Laboratories) was injected by tail vein and allowed to circulate for 2 min, and then the mouse was perfused with 1% PFA through the left ventricle. Paraffin sections of liver were developed with streptavidinHRP and photographed at 20× magnification.
Transfections. Human IRS2 promoterluciferase constructs containing wildtype sequence or mutations of the distal (-900mut) or proximal (-123mut) HREs were generated by sitedirected mutagenesis and transfected into mouse H2 hepatocytes with internal Renilla luciferase control in the pres ence of AdGFP, AdHIF2α∆ODD or AdHIF1α∆ODD.
Microarray analysis. For comparison of gene expression, 8 to 10weekold female SCID C17 mice were injected with VEGF Trap (n = 5) or hFc (n = 4) at 25 mg per kg body weight twice weekly for 9 weeks. RNA from liver was extracted as described above and 30 µg of total RNA was used to generate cDNA. Hybridization of sample cDNA to Mouse Exonic Evidence Based Oligonucleotide (MEEBO) arrays was performed by the Stanford Functional Genomics Facility (SFGF). Statistical analysis of gene expression was per formed using Significance Analysis of Microarrays software (SAM) and heat map representation was generated through TreeView.
Statistical analyses. All bars show mean ± s.e.m. Significance was calculated using a Student's ttest or oneway analysis of variance with NewmanKeuls post hoc test for comparison of groups greater than two. *P < 0.05.
